Case Reports
Journal Article
Add like
Add dislike
Add to saved papers

UNREPORTED SIDE EFFECT OF INTRAVITREAL DICLOFENAC IN CHRONIC DIABETIC MACULAR EDEMA.

PURPOSE: To evaluate the safety and efficacy of intravitreal diclofenac sodium.

METHODS: A 61-year-old male with persistent diabetic macular edema was treated with 450 μg of intravitreal diclofenac sodium (systemic preparation).

RESULTS: Postinjection Day 1, the spectral domain optical coherence tomography showed irregular vitreoretinal interface with wrinkling and separation of the internal limiting membrane from the nerve fiber layer with homogeneity of the inner layers. At 1 month, the compactness of the retinal layers was restored. Complete resolution of the cystoid macular edema was seen. At 1 year, there was mild flattening of the foveal depression with epiretinal membrane.

CONCLUSION: Various studies have shown the safety and efficacy of intravitreal diclofenac without any reported side effect. We report the inner retinal toxicity in the form of cystic spaces and splitting of internal limiting membrane from nerve fiber layer on the first follow-up day, postinjection, which resolved over a period of 1 month. Further studies are needed to assess the safety of intravitreal diclofenac sodium.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app